

AlphaVax Announces \$11 million in Series C

DURHAM, N.C. -- AlphaVax Inc. today announced that it has successfully completed a private placement of its Series C convertible preferred securities, raising \$11 million. Investors in this round of financing included both U.S. and European institutions. Burton Advisers Ltd. acted as the exclusive placement agent and provider of financial advice to AlphaVax during the financing round.

"We are very pleased with this round of financing. Together with the Series B round concluded in February, AlphaVax has raised more than \$19 million this year. We welcome this additional support as both a strong vote of confidence by our investors in the company's progress, and a tremendous springboard for our expanding forward objectives," said Peter F. Young, President and CEO of AlphaVax. "With these funds, we can initiate new in-house product programs to establish our own product pipeline, as well as begin taking up second-generation systems and new technologies that will extend the company's long-term strategic platform."

"The value of our products and platform were recognized by our current investors, who represented 40 percent of the round; as well as by new investors including investment funds, individual investment bankers and professionals, and banking institutions," said Tim C. Gupton, company's CFO. "Our funding success is especially significant, given the uncertainty in the capital markets."

The company is currently working to develop and commercialize a proprietary vaccine vector technology with properties that show significant promise in creating better and more effective vaccines. The company has recently focused on establishing the technology's regulatory and manufacturing platform, and anticipates its first clinical trials to begin in the first quarter of next year. AlphaVax is also actively expanding its organization and is in discussions with a growing list of potential corporate partners, including established vaccine manufacturers and biotech companies.

AlphaVax received considerable attention at the recent XIIIth International AIDS Conference held in Durban, South Africa. Robert Johnston, PhD, Chairman; Peter Young, CEO; and Robert Olmsted, PhD, VP of Research, spoke at the conference. The company is based in Durham, N.C.